0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

The impact of inflammation on prostate tumor dynamics: a pathological perspective on prostate cancer and benign prostatic hyperplasia

Authors

Introduction: Chronic inflammation is associated to the pathogenesis of prostate cancer (PCa) and benign prostatic hyperplasia (BPH). This study evaluated the correlation between inflammatory markers fibroblast growth factor-2 (FGF2), interleukin (IL)-8, and IL-6 in PCa and BPH tissues to understand their involvement in disease progression.
Methods: A cross-sectional investigation was carried out, examining prostate specimens from 62 male patients diagnosed with PCA or BPH. Specimens were taken via transurethral resection of the prostate (TURP) and stained with hematoxylin and eosin to look for inflammatory infiltrates and aggressiveness. The levels of FGF2, IL-8, and IL-6 were evaluated using ELISA. Chi-square and logistic regression tests were used in the statistical analysis.
Results: High-grade inflammation was found in all BPH cases (100%), but not in PCa cases. In BPH tissues, elevated levels of IL-8 and IL-6 had a significant correlation with high-grade inflammation (p < 0.05). On the other hand, PCa tissues had considerably greater FGF2 levels than benign tissues (p < 0.05). Elevated FGF2 levels and the lack of high-grade inflammation in PCa tissues point to different pathogenic processes in PCa and BPH.
Conclusions: This study emphasizes the importance of chronic inflammation in BPH development, with IL-8 and IL-6 playing essential roles. The results imply that treating BPH by focusing on IL-8 and IL-6 may be beneficial. Increased levels of FGF2 in PCa tissues suggest that this protein may be used as a biomarker and therapeutic target for PCa. These findings highlight the importance of targeting both inflammatory and growth factor pathways for treating prostatic disorders.

Tang J, Yang J. Etiopathogenesis of benign prostatic hypeprlasia. Indian J Urol. 2009; 25:312-7.
Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol. 2014; 66:619-622.
Sampson N, Madersbacher S, Berger P. Pathophysiology and therapy of benign prostatic hyperplasia. Wien Klin Wochenschr. 2008;120:390-401.
Guner E, Danacioglu YO, Arikan Y, et al. The presence of chronic inflammation in positive prostate biopsy is associated with upgrading in radical prostatectomy. Arch Ital Urol Androl. 2021; 93:280-284.
De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol. 2011; 60:106-117.
Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev
Immunol. 2018; 18:773-789.
Moore RA. Inflammation of the Prostate Gland1. J Urol. 1937;38:173-182.
Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013; 112:432-441.
Delongchamps NB, de la Roza G, Chandan V, et al. Evaluation of Prostatitis in Autopsied Prostates: Is Chronic Inflammation More Associated with BPH or Cancer? J Urol. 2008; 179:1736.
Oseni SO, Naar C, Pavlovic M, et al. The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic
Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer. Cancers (Basel). 2023; 15:3110.
Penna G, Fibbi B, Amuchastegui S, et al. Human Benign Prostatic Hyperplasia Stromal Cells As Inducers and Targets of Chronic Immuno-Mediated Inflammation. J Immunol. 2009; 182:4056-4064.
Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010;33:475-488.
Elkahwaji JE. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol. 2013; 5:1.
Nickel JC, True LD, Krieger JN, et al. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001; 87:797-805.
Irani J, Levillain P, Goujon JM, et al. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol. 1997; 157:1301-1303.
De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7:256-269.
Sfanos KS, de Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012; 60:199-215.
Murtola TJ, Gurel B, Umbehr M, et al. Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2016; 25:463-469.
Stone L. FGF2 causes genomic instability. Nat Rev Urol. 2018;15:528-528.
Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options. Int J Urol. 2024; 31:968-974.
Syahrir S, Hatta M, Warsinggih W, et al. Propionebacterium acnes associated with inflammation in benign prostatic hyperplasia. Int Med J. 2020; 25:13412051.
Gurel B, Lucia MS, Thompson IM, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014; 23:847-856.
Pecqueux C, Arslan A, Heller M, et al. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer. Urol Oncol. 2018; 36:365.e15-365.e26.
Ropiquet F, Giri D, Lamb DJ, Ittmann M. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol. 1999; 162:595-9.
Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007; 51:1202-1216.
Robert G, Descazeaud A, Nicolaïew N, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009; 69:1774.
De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol. 2007; 25:398-400.
Rose-John S, Jenkins BJ, Garbers C, et al. Targeting IL-6 transsignalling: past, present and future prospects. Nat Rev Immunol. 2023; 23:666-681.
Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014;192:16-23.
Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10:116-129.
Schaeffer EM, Srinivas S, Adra N, et al. Prostate Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2024; 22:140-150.
Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw. 2021; 19:134-143.

How to Cite

Syahrir, S., Palinrungi, M. A., Hatta, M., Kholis, K., Syarif, S., Azis, A., & Faruk, M. (2025). The impact of inflammation on prostate tumor dynamics: a pathological perspective on prostate cancer and benign prostatic hyperplasia. Archivio Italiano Di Urologia E Andrologia, 97(1). https://doi.org/10.4081/aiua.2025.13353

Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.